Introduction
Peptide YY (PYY), am ember of the pancreatic polypeptide family, [1] [2] [3] [4] [5] [6] [7] [8] was first isolated from porcine intestinal tissue extracts in 1980 [9] and was later shownt ob eac ritical enteroendocrine hormone involved in appetite regulation. [10] [11] [12] PYYh as two main circulating forms:P YY and at runcated form, PYY . [13] PYY i sr eleased in concert with caloric intake or exercise andi sc leaved by dipeptidyl peptidase IV (DPP-IV) [14] in the gut to produce PYY . PYY has an appetite-stimulating effectt hrough activation of the orexigenic Y1 receptor (Y1-R) located in the intestines, blood vessels,a nd brain. [15] The two-amino-acid N-terminal (Tyr-Pro) truncation to PYY resultsinanapproximate 100-fold decrease in activity at the Y1-R, [5, 16] and generates an agonist of the anorexigenic Y2 receptor (Y2-R)l ocated in the intestines (vagal afferent sensory neuron signaling) [17, 18] and brain, [19, 20] whiche xerts aGprotein-coupled receptor (GPCR) G i -mediated anorectic effect.
We recently reported aB 12 -PYY(3-36)c onjugate that demonstrated similara ctivity to native PYY at the Y2-R in vitro, but improved function over PYY ) upon subcutaneous (s.c.) administrationi nvivo in al ean rat model (conjugate 3 as described herein below). [21] In earlier work, we focusedo nc onjugating to B 12 through the ribose hydroxy group, as it is well established in the field that this is an optimal site for such conjugation, as it does not hinderr ecognition of B 12 by its carrier proteins. [22] [23] [24] [25] Likewise, we focused on an N-terminal region of PYY f or conjugation (specifically the K 4 residue), because again it has been well documentedt hat modifications at (or indeedc ompletel oss of) this area do not significantly affect Y2-R agonism. [26] [27] [28] These assumptions bore out, as the EC 50 valuesa tt he Y2-R obtained for the conjugatep roduced (and noted as conjugate 3 herein)w ere similart ot hat of unconjugated PYY(3-36) used for comparison. These were established using aF ura-2 assay that monitors intracellular Ca 2 + mobilization under conditions in which the Y2-R signals through ap romiscuous G q GTP binding protein. [21] Questions that remained from this work, however,w ere what affect, if any,d oes B 12 conjugation actually have on the PYY(3-36) secondary structure and whether MD simulations could be used to better understand, and possibly predict, any structuralm odificationso bserved. To investigate these questions, two conjugates located at the same coupling sites (ribose on B 12 and K 4 on PYY Vitamin B 12 -peptide conjugates have considerable therapeutic potentialt hrough improved pharmacokinetic and/or pharmacodynamic properties imparted on the peptideu pon covalent attachment to vitamin B 12 (B 12 ). There remains al ack of structural studies investigating the effects of B 12 conjugation on peptides econdary structure. Determining the solution structure of aB 12 -peptide conjugate or conjugates and measuring functions of the conjugate(s)a tt he target peptide receptor may offer considerable insightc oncerning the future design of fully optimized conjugates. This methodology is especially useful in tandem with constrained molecular dynamics (MD) studies, such that predictions may be made about conjugates not yet synthesized.F ocusing on two B 12 conjugates of the anorectic peptide PYY , one of which was previously demonstrated to have improved food intake reduction compared with PYY(3-36), we performed NMR structurala nalyses and used the information to conduct MD simulations. The study provides rare structurali nsight into vitaminB 12 conjugates and validates the fact that B 12 can be conjugated to ap eptide without markedly affecting peptide secondary structure.
but with as lightly varying spacerl ength (one methylene unit difference) were assayed for agonismo ft he Y2-R using an ew fluorescencer esonance energy transfer (FRET)-based assay that faithfully reports the normals ignal transductionp rocess by which the Y2-R signals throughG i proteins to lower levels of intracellular cyclic adenosine monophosphate (cAMP). [29] NMR structures weres olved for these conjugates, and their in-solution NMR structures were compared with those previously reported by Keire et al. [30] and Nygaard et al. [7] Subsequent unconstrained and NMR constrained MD simulations were then also performed.
Results and Discussion
In vitro evaluation of conjugates 3a nd 4
All assays were performed at least in triplicate. Conjugates 3 and 4 were tested for their abilities to lower cAMP levels. Figure 1s hows the dose-response relationships for 3 and 4 relative to K 4 PYY,s howing both conjugates are less active than K 4 PYY and that 4 is more active than 3.B oth conjugates are, however, within one-half log order of K 4 PYY.
This difference in EC 50 values in comparing conjugates with K 4 PYY was initially presumed to be ac ompromise between steric hindrance and/or unfavorable flexibility resulting in modifications/interactions that negatively affect the peptide structure-activity profile. At this point we decided to pursue NMR and molecular dynamics (MD) studies to further explore these in vitro observations.
NMR analysis of 3a nd 4
Proton chemical shifts for 3 were assigned by analyzing TOCSY, DQF-COSY,a nd 2D NOE spectra at 25 8C. The experiments were also performed at2 0a nd 30 8C, at which slight shifts of some proton signals resolved overlapping peaks. The NMR spectra of 3 have some similarity to those of PYY , such as line broadening of many signals, [7] indicating increased dynamics, and ad ecrease in the chemical shiftr ange of the backbone amide protons relative to full-length PYY.A ll backbonea mide protonsw ere assigned with the exceptiono fL eu24, which could not be definitely determined due to overlap.F igure S17 (Supporting Information) shows the proton chemical shift differenceb etween 3 and PYY . There are chemical shift differences for residue Lys4, which is not surprising, as this is the attachment site for B 12 .F igure 2s hows an overlay of 3 after MD calculations and PYY . The first chemical shift difference to consideri st hat for the methyl and a protons of Ala7. In PYY , the methyl group of residue Ala7 is pointing toward the a helix, whereas in conjugate 3 the methyl group is oriented away from the a helix. A2 DN OE cross-peak between the Ala7 methyl group and the ring protons of Tyr20 was observedi nP YY , [7] but in 3 only av ery weak crosspeak was observedi nt he longest mixing time 2D NOE experiment. This difference in orientation would also put the Ala7 a protoni nd istinct environments. The backbone amide protons have different chemical shifts for the b turn residues and residues in the N-terminal side of the a helix, specifically residues Gly9, Ala12, Ser13, Glu15, Leu17, and Arg19. This can be explained by the unraveling of the a helix andi ncreased dynamics at the N-terminal side in the PYY(3-36) structure.C onjugate 3 maintains an a-helical structure similar to that of fulllength PYY,a nd the residue with the largest chemical shift difference for the amide proton, Leu17, has ac hemical shiftv alue closer to thato ft he full-length peptide: PYY Leu17 NH 8.40 ppm, [7] 3 Leu17 NH 8.36 ppm, PYY(3-36) 7.95 ppm. [7] Nygaard et al. suggestt hat the Pro2-Tyr27 interaction is important forthe stabilityo fthe PP fold, and that loss of this interaction in PYY creates both conformational and dynamic changes in the structure, especially around the turn region. [7] Close inspection of 3 indicates possible hydrogen bonds from Glu6 to Tyr27 and Ser23,w hich may stabilizet he PP fold in the conjugate. [7] was obtainedf rom the RCSB Protein Data Bank (www.pdb.org);PDB ID: 2DF0. The program Chimera (UCSF;www.cgl.ucsf.edu/chimera/) [31] was used to display the image. To elaborate on the structural studies, we decided to also investigatet he solution structure of 4 to allow ad irect comparison with 3.B ased on the NMR spectra, the conjugate structures appear very similar with only minor differences in the proton chemical shifta ssignments (Supporting Information Figure S18 ) and greater than 95 %s imilarity in the 2D NOE spectra (Supporting Information FigureS19).
The major difference observed between 3 and 4 is the proton chemical shiftc hange at B7 and B2 on the dimethylbenzimidazole (DMB)l igand (see Supporting Information Figure S12 for B 12 atom numbering scheme). The C20 methyl protons are closer to the B4 and B2 protons in 4 based on the presenceo faweak cross-peak between the C20 methyl protons andB 2, whichi so nly seen in the longest mixing time 2D NOE spectra of 3,a nd ac ross-peak between the methyl protons and B4, which is strongerf or 4.W eak cross-peaks are observed in 4 between ap ropionamide protono ft he g side chain of B 12 (Supporting Information Figure S12 ) and the Ha of D11a sw ell as the methyl protons of A12. The a helix motif as aw hole is criticalf or association and subsequent agonism. [26] This is consistentw ithr eported Y2-R interactions, as the C-terminal pentapeptide region is well established as the critical region, or "address",o ft he main interactions with Y2-R, while the a helix is considered the "message", indicating that both areas are critical in Y2-R agonism. [26] NMR constrained MD studies of 3and 4
Molecular dynamics simulations of 3 and 4 were performed both with and without the NMR constraintsd efined for 3 to consider differences in behavior and potential alternative structures in the simulations. The observeds tructural changes across the simulations identifiedi ntra-PYY interactions that might, through their stabilization in the isolated conjugate, promote the decreased activity of 3 relative to 4.T he unconstrained MD simulationd ata then providea na dditional set of structures for considering accessible geometriesb eyond the restrained set. The average structures from representative MD time ranges for 3 and 4 are shown in Figures 3( front/side view) and 4( top view). Apparent from these views,a nd the full simulations in general,a re the persistenceo f1 )much of the a helical structure and 2) localization of the B 12 fragment itself to the unstructured region approaching the loop into the a helix (in the images, this loop is at the base of all structures, including residues Glu10, Asp11, and Ala12). Across all of the simulations, several hydrogen bonding motifs are found to persist at the onset of the simulations and over the time evolution of the structure dynamics that serve to effectively anchor the B 12 at this loop region. Those whichs pecifically anchor the B 12 to this region in all simulations are shown in Figure 5 , visualizing the two most persistentm otifs for theses tructures: ap air of hydrogen bonds from as ingle B 12 amide side chain to Pro8 and Glu16( left, Motif 1) and an amide side chain to Pro8 hydrogenb ond and coordinationo fahydroxy group Ha tom on Ser13 to the B 12 cyano nitrogen atom (right,M otif 2). The structuralb asis for preservation of the loop region itself across all simulations is evident in Figure 6 , which showst hat (left) Glu16 is engaged in several persistenthydrogen bondinginteractions with Gly9, Glu10, and Asp11, whereas at the far end of the loop (right), Glu6 is in close proximity to hydrogen bond acceptors on Tyr27 and Ser23. The NMR distance lists, ranges, and time-averaged MD structures for 3 and 4 are provided in the Supporting Information.
The differences between structures 3 and 4,b oth with and withoutNMR constraints, are largelyl ocalizedt ot he C-terminal side of the a helix and occur to varying degrees in all of the simulations. With the B 12 largely predicted to be confined to the PYY(3-36) loop due to several strong hydrogen bonding interactions, and with the well-known attenuationo fP YY(3-36) activity with modificationst oo rr emoval of the C-terminal region, the most logical explanationf or any change in behavior to come from these single conjugate simulations is some structuralc hange at the C-terminal region of PYY . This may occur from B 12 binding-induced conformational changes at the PYY Nterminus, causing changes in activity,m eaning any observedi nteractions between the B 12 binding-constrained Nterminus and concomitantly proximal C-terminalr egions are of great interest. Despite the small change in tether length for these two cases, RMSD analyses and average structure generation produced two distinct structures that, for each case, revealed binding interactions deemed consistent with the trends in activity.
MD simulations of 3 and 4 highlight hydrogen bonding interactions that may govern the differences observed in Y2-R agonisma nd subsequent calcium mobilizationa nd inhibitory cAMP effects. PYY(3-36) does not tolerate any interaction at the Cterminus with respectt oY 2-R stimulation. [32] If the answer to the decreased activity of 3 lies solely on some response internal to the conjugate,o ne might argue from the MD simulationst hat the shortenedt ether length enhances the stiffness of the unstructured region (residues 3-9) by decreasing its conformational flexibility upon hydrogen bonding between the B 12 andt he near-loop region. This result would provide al ess flexible N-terminal region and am ore persistenth ydrogen bonding pocket for the C-terminal region with which to interact. By the loss of flexibility,n ecessary at the C-terminal region for biological activity,reduced activity would be predicted (and is observed). Kaiser et al. recently reported data showing that unwinding of C-terminal residues of neuropeptide Y (NPY) is critical for Y2 receptor binding and activation. [32] Solution NMR experiments showedt hat the ligand is tethered to the second extracellular loop by hydrophobic contacts and revealed NPY to undergo remarkable structural changes within the Cterminus. The C-terminal pentapeptide plays ar ole in extensivea nd susceptible interactions in NPY;anetwork that is also relevant for PYY in regards to Y2-R agonism. Changes in the C-terminala mino acids can easily disturbr eceptor bindingo rs witch receptor selectivity for both NPY and PYY(3-36)a so bserved in numerouse arlier structure-activity studies. [33] The ultimate conclusion from Kaiser et al. directly relates to our work, as the binding mode of NPY[ and in our case, B 12 conjugateso fP YY(3-36)] might have more general implications for peptideb inding GPCR systems.
The MD simulations from this study do indicatet hat if the origin of the decreased activity of 3 is entirely duet of actors internal to the B 12 -PYY(3-36) conjugatei tself, then constraint of the C-terminal region by hydrogen bonding interactions with the N-terminal region could explain it-and that this kind of internal mechanism mayh ave its origin in the reduction of tether length. show similar Y2-R agonism to that of PYY . Both intra-and intermolecular interactions between B 12 and the peptidea nd small changes in the secondary structure of the peptide brought on by conjugation wereo bserved. Based on the information collected from the NMR constrained MD studies, it would have been possible to offer ad etailed assessment of the potential functiono fb oth conjugates. These observations suggest that MD could be used apriori to guide conjugate rational design and minimize the number of conjugatest hat would need to be screened-information of considerable benefiti nd evelopment terms.C onjugates and modifications of B 12 have garnered much interest in recent years for their clinical and medicinal applicability. [34] Based on the studies described herein, an ideal B 12 -peptide conjugate would be one with an appropriate linker length to allow optimal function of both the peptide and B 12 ,w hich could be predicted by MD via inter-and intramolecular interactions that are knownt ob eu seful and/or harmful to the overall functionofe ach component.
Conclusions

Experimental Section
Synthesis of alkyne precursors (1 and 2) and conjugates (3 and 4):T wo B 12 -alkyne precursors were prepared by activation of aB 12 carboxylic acid (B 12 -CA) derivative [35] with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and hydroxybenzotriazole (HOBt) in anhydrous DMSO under argon (Scheme 1). Full characterization of the alkyne precursor 1 and 2,i ncluding RP-HPLC, MALDI-ToF MS, and NMR can be found in the Supporting Information ( Figure S1 -11,T able S1). For conjugate synthesis, click chemistry [36] was implemented using ac opper iodide (CuI) and tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) method, adapted from Gryko et al. [37, 38] Copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) synthesis of conjugates 3 and 4 via the alkyne precursors 1 and 2 and aK 4 -azido PYY(3-36) (K 4 PYY) is described in Scheme 2( spacer length n = 2, 3f or precursors 1a nd 2). K 4 PYY was initially tested against PYY(3-36) amide (Sigma-Aldrich), and there was no observed difference in Y2-R agonism. Subsequently,K 4 In vitro assay of 3and 4a tthe Y2 receptor coupled to G i :Conjugates 3 and 4 were tested for their abilities to lower levels of cAMP in an in vitro assay using HEK293 cell monolayers ( Figure 7) . [29] These cells were engineered so that they stably express the human GLP-1 receptor (GLP-1R), while also transiently expressing the human Y2-R. Furthermore, these cells were virally transduced with the genetically encoded FRET reporter AKAR3, which is used to monitor cAMP-dependent protein kinase (PKA) activation intracellularly.T his assay is unique in that it allows FRETbased detection of the ability of PYY to counteract the action of aG LP-1R agonist (Exendin-4;Ex-4) to raise levels of cAMP. When the cells are first treated with Ex-4 (33 pm;i njection 1) so that levels of cAMP are elevated, AKAR3 exhibits increased FRET, measured as ad ecrease in the 485/535 nm emission ratio ( Figure 7 ). This change of FRET occurs after an approximate lag time of 50 s. If PYY is then applied at the 180 st ime point (injection 2), af unctional antagonism of the action of Ex-4 is measured so that the change of FRET is decreased. Note that no change of FRET is measured in response to the administration of an egative control standard extracellular saline (SES;F igure 7). By varying the concentration of added conjugate, it is possible to determine dose-response relationships, and to also determine EC 50 values describing inhibitory actions of PYY conjugates versus 33 pm Ex-4 in this assay.F igure 7i llustrates these responses to the first injection of either Ex-4 or SES, and the second injection of K 4 PYY or SES. To normalize these raw data for subsequent dose-response analysis, "end-point" values of FRET were measured during the last 10 sample intervals ( Figure 7 ). As illustrated in Figure 1 , the dosedependent inhibitory actions of PYY conjugates are then quantified relative to av alue of 100 %t hat corresponds to the maximal inhibitory effect measured when testing 300 nm PYY(3-36) in this assay.
NMR studies of 3and 4:NMR studies were executed initially to observe any structural differences between the conjugates and free peptide in solution. Because in vivo studies had previously established in vivo function for 3, extensive structural studies were first performed with 3 and ad irect comparison made to published PYY . [7] Full NMR studies of 4 were then completed to serve as MD studies of 3a nd 4:T oc omplement the NMR studies, MD simulations of 3 and 4 were completed in attempts to explain the minor differences of Y2-R agonism between the two conjugates. These MD studies took the form of 50 ns simulations to probe the potential variation in simulation geometries and time-averaged structures that arise from different tether lengths. MD simulations were performed using the GROMACS (ver.5.0.4) [39] software package. The NMR distance lists, ranges, and tabulated distances from the time-averaged MD structure for 3 are provided in the Supporting Information. Table S1 for labeling schematic.
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